Puma Biotechnology (PBYI) Q1 2025 earnings summary

Executive summary

• Q1 2025 net income was $3.0 million ($0.06/share), reversing a net loss of $4.8 million in Q1 2024, with non-GAAP adjusted net income at $5.0 million ($0.10/share).

• Total revenue for Q1 2025 was $46.0 million, up from $43.8 million year-over-year, driven by NERLYNX net product revenue of $43.1 million and royalty revenue of $2.9 million.

• NERLYNX bottle sales were 2,338 in Q1 2025, down 21% quarter-over-quarter and 3% year-over-year, impacted by a $4.7 million inventory decrease.

• 72% of new patients in Q1 2025 started at a reduced dose, continuing a trend from previous quarters.

• Ongoing clinical programs include phase 1/2 trials for neratinib combinations and alisertib in breast and lung cancer, with key milestones expected in H2 2025.

Financial highlights

• Net product revenue from NERLYNX was $43.1 million, up from $40.3 million in Q1 2024 but down from $54.4 million in Q4 2024; royalty revenue was $2.9 million, down from $3.5 million year-over-year.

• Cost of sales was $10.6 million, including $2.4 million amortization of intangible assets, and remained nearly flat year-over-year.

• SG&A expenses were $17.6 million (down 19% year-over-year), and R&D expenses were $13.8–$13.9 million (up 2%).

• Cash, cash equivalents, and marketable securities totaled $93.2 million at March 31, 2025, down from $101.0 million at year-end 2024.

• Net cash provided by operating activities was $3.6 million for Q1 2025.

Outlook and guidance

• FY 2025 net NERLYNX product revenue expected between $192 million–$198 million; royalty revenue guidance is $20 million–$24 million.

• FY 2025 net income guidance is $23 million–$28 million.

• Q2 2025 net product revenue guidance is $48 million–$50 million; Q2 net income expected at $4 million–$6 million.

• Gross-to-net adjustment expected at 20.5%–21.5% for 2025.

• Management believes current cash and equivalents are sufficient to fund operations for at least one year.